Slide 1: Cover letter to stock exchanges: Investor Updates for quarter ended 31 December 2024
Date: 07 February 2025 To To National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Bandra Kurla Phiroze Jeejeebhoy Towers, Dalal Street Complex, Bandra (E), Mumbai – 400 051 Mumbai – 400001 NSE Scrip Symbol: SaiLife BSE Scrip Code: 544306 Sub: Investor Updates for the qu
Slide 2: Sai Life Sciences Limited Earnings Presentation
Sai Life Sciences Limited Earnings Presentation February 07, 2025
Slide 3: Message from Managing Director & CEO
Message from Managing Director & CEO “ We are pleased to announce a healthy performance this quarter, driven by strong execution, expanding capacity, and deepening customer relationships. Our integrated CRDMO model continues to differentiate us in the market, enabling us to provide seamless solution
Slide 4: Message from Chief Financial Officer
Message from Chief Financial Officer “ We are delighted to share our Q3 FY25 financial performance, which highlights robust business momentum, operational discipline, and strong customer relationships. Revenue from operations grew to ₹439.8 Cr, up 15% from ₹383.6 Cr in Q3FY24, on account of continue
Slide 5: Quarter Highlights
“ Sai Make it better together Quarter Highlights
Slide 6: Performance Snapshot
Performance Snapshot Q3FY25 Q3FY25 Q3FY25 REVENUE EBITDA PAT ₹ 440 Cr 15%YoY Growth ₹ 124 Cr 19%YoY Growth ₹ 54 Cr 36%YoY Growth 9MFY25 9MFY25 9MFY25 REVENUE EBITDA PAT ₹ 1,115 Cr 9% YoY Growth ₹ 264 Cr 50%YoY Growth ₹ 82 Cr 207% YoY Growth Continued momentum in both Improved operating PAT Expansion
Slide 7: Key Financial Highlights
Key Financial Highlights Revenue (₹ Cr) EBITDA (₹ Cr) and Margin (%) PAT (₹ Cr) 28% 54 27% 27% Q U A RT E R LY 440 124 40 42 396 109 384 104 Q3FY24 Q2FY25 Q3FY25 Q3FY24 Q2FY25 Q3FY25 Q3FY24 Q2FY25 Q3FY25 YoY Growth 15% QoQ Growth 11% YoY Growth 19% QoQ Growth 15% YoY Growth 36% QoQ Growth 30% 24% 1,
Slide 8: Operating Highlights: Key Business Updates
Operating Highlights: Key Business Updates CAPITAL EXPENDITURE • Capital expenditure for 9MFY25 was ~₹300 Cr CDMO CRO • The Company has added an additional 100 KL in November to its manufacturing capacity. The Company further expects to add an additional 100 KL in Q1FY26. 9MFY25 • The Company has ex
Slide 9: Company Overview
“ Sai Make it better together Company Overview
Slide 10: Sai Life Sciences at a Glance
Sai Life Sciences at a Glance One-stop 25+ platform 3,000+ 300+ Years of experience for discovery, Total employees Active customers across US, UK, EU, (Incorporated in 1999) development and manufacturing Japan USFDA, PMDA Diverse 10+ 100% successful track record of therapy areas 18/25 Oncology, CNS,
Slide 11: Experienced Management Team and Board Supported by a Qualified Scientific Talent Pool
Experienced Management Team and Board Supported by a Qualified Scientific Talent Pool Supported by an Experienced Founder and Management Team with Average 25+ Years of Industry Experience Experienced Board Kanumuri Ranga Raju 25+ Krishna Kanumuri 20+ Mitesh Daga Chairman and Whole time Managing Dire
Slide 12: Key Milestones
Key Milestones Expanded Acquired additional manufacturing Successful FDA Unit II Expansion: facilities capacity inspection Advancing R&D for to include process by acquiring a 40KL of GMP Manufacturing Pharma CDMO Added 100KL R&D capabilities – Launched small- site, Unit IV Animal Facility expanded P
Slide 13: Sai Life Sciences – A Leading CRDMO with scaled operations across both verticals
Sai Life Sciences – A Leading CRDMO with scaled operations across both verticals Sai Life Sciences operates as both a Contract Research Organization (CRO) and a Contract Development & Manufacturing Organization (CDMO), offering an end-to-end platform for global pharmaceutical and biotech companies C
Slide 14: Modern R&D and Manufacturing Infrastructure
Modern R&D and Manufacturing Infrastructure Discovery Biology Process R&D Integrated Discovery and API Manufacturing Lab, Greater Boston Laboratory, Manchester Development Facility, Hyderabad Facility, Bidar • Laboratory equipped for fit-for-purpose • Centre of excellence in • Fully integrated R&D c
Slide 15: Long Standing Customer Base
Long Standing Customer Base Top 25 Global Pharma Companies(1) Johnson & Johnson Viatris Pfizer Vertex Pharmaceuticals Serve 18 of 25 top global pharma companies(1) Novo Nordisk Merck Bayer AstraZeneca Astellas Pharma Amgen AbbVie CSL Serve 280+ Innovator Pharmaceutical Companies Sanofi Sandoz and Bi
Slide 16: The CRDMO Market Opportunity
The CRDMO Market Opportunity 1 Small Molecules with over 65% contribution(1) dominate the Global Pharma Market 2 72% of 302 FDA approved drugs in 2018–23 were small molecules NCE (New Chemical Entities) Increasing Outsourcing Across the Pharma Value Chain 3 • Global Small Molecule Non-clinical CRO I
Slide 17: Annexure
“ Sai Make it better together Annexure
Slide 18: Consolidated Statement of Profit and Loss
Consolidated Statement of Profit and Loss Particulars (₹ crores) Q3FY25 Q2FY25 Q3FY24 9MFY25 9MFY24 FY24 Revenue from operations 440 396 384 1,115 1,026 1,465 Other income 4 4 3 11 11 14 Total income 444 400 387 1,126 1,037 1,479 Expenses Cost of materials consumed and changes in inventories 121 104
Slide 19: Awards & Recognitions
Awards & Recognitions Awarded as “Excellent Winner of Gold in Brandon Energy Efficient Unit” Hall Group’s Excellence in Excellence in Digitalizing at CII’s 24th National Technology Awards in “Best Learning & Development, Energy Management Advance in Content 2023 by ISTD Awards for the fourth Authori
Slide 20: Glossary
Glossary APIs Active pharmaceutical ingredients Biotechnology companies, often referred to as biotech companies, are largely startups in the pharmaceutical sector which typically focus on developing innovative drugs and drug Biotechs development technologies to address unmet medical needs Blockbuste
Slide 21: Safe Harbor
Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "p
Slide 22: Thank You
Thank You For more details please contact: Investorrelation@sailife.com © Sai Life Sciences Limited. L4, SLN Terminus, Gachibowli, Hyderabad 500032, Telangana, India.